A year after missing on a trial endpoint, Travere Therapeutics can breathe a sigh a relief. | A year after missing on a trial ...

GSK is heading into the weekend with a win for its respiratory blockbuster Nucala—but for now, the details are slim. On ...

After running up against a roadblock earlier this summer, the controversial BIOSECURE Act could gain new momentum next week.

AstraZeneca has found its employees’ practices under the microscope of Chinese law enforcement years after an insurance fraud ...

Madrigal Pharmaceuticals broke new ground earlier this year as its Rezdiffra became the first drug approved by the FDA to ...

With dwindling funds after a prior snub from the FDA, ImmunityBio’s journey to bag approval for its Merck-rivaling bladder ...

Astellas is closing a gene therapy manufacturing facility in South San Francisco. But, across the country, the company opened ...

It’s as you were at the top of the TV drug ad spending table as AbbVie continues its 2024 domination as total spending across ...

After handing over $30 million in criminal penalties last summer, Glenmark Pharmaceuticals has agreed to settle with the U.S.

After years of documentation and industry neglect, the World Health Organization (WHO) issued its first-ever guidance aimed ...

Even though dementia is widespread—with more than 55 million people around the world currently affected and 10 million new ...

In his nine months as CEO, BioMarin’s new chief Alexander Hardy has so far overseen shakeups in the company’s leadership team ...